KRAS G12D inhibitor INCB161734: from oral tool compound to clinic
- Starting from an orally available tool compound, chemists tuned potency and pharmacokinetics together to lower the projected human dose.
- Mapping where the molecules were metabolized pointed to analogs with low clearance.
- Keeping size modest and raising sp3 character improved permeability and crystalline solubility.
- The result, INCB161734, offers strong oral exposure, suppresses xenograft tumor growth, spares wild-type RAS isoforms, and is now in clinical trials.
💡 Points Based on the abstract
Cutting projected human dose through metabolite-ID-driven clearance fixes and higher Fsp3 is the standard playbook for a basic, polar G12D chemotype, where permeability usually sinks you. Open questions: whether the wild-type RAS sparing is real selectivity or just a cell-assay window, and how it compares with MRTX1133, which struggled to reach oral exposure.
Discovery of INCB161734: A Selective Inhibitor of the KRAS G12D Mutant ↗